PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone — Dec 2nd, 2024

Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged. Continue reading View comments...

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer — Oct 18th, 2024

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer On Friday, Novartis AG (NYSE:NVS) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for ...

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer — Oct 18th, 2024

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer On Friday, Novartis AG (NYSE:NVS) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for ...

Novartis Sacrifices A Flat Base On Lagging Sales Of Its Biggest Moneymaker — Oct 29th, 2024

Novartis stock slumped Tuesday — undercutting the lower boundary of a flat base — after sales of its biggest moneymaker expectations. Continue reading View comments...

Novartis Sacrifices A Flat Base On Lagging Sales Of Its Biggest Moneymaker — Oct 29th, 2024

Novartis stock slumped Tuesday — undercutting the lower boundary of a flat base — after sales of its biggest moneymaker expectations. Continue reading View comments...

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone — Dec 2nd, 2024

Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged. Continue reading View comments...

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer — Oct 18th, 2024

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer On Friday, Novartis AG (NYSE:NVS) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for ...

Novartis Sacrifices A Flat Base On Lagging Sales Of Its Biggest Moneymaker — Oct 29th, 2024

Novartis stock slumped Tuesday — undercutting the lower boundary of a flat base — after sales of its biggest moneymaker expectations. Continue reading View comments...

Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU — Oct 17th, 2024

Alnylam Pharmaceuticals ALNY announced that it has submitted a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM). Shares of the company gained 4.6% in response to t...

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer — Oct 18th, 2024

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment with Kisqali® (ribociclib) in combination with an aromatase inhibitor1 Recommendation i...

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer — Oct 18th, 2024

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer On Friday, Novartis AG (NYSE:NVS) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for ...

Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU — Oct 17th, 2024

Alnylam Pharmaceuticals ALNY announced that it has submitted a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM). Shares of the company gained 4.6% in response to t...

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer — Oct 18th, 2024

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment with Kisqali® (ribociclib) in combination with an aromatase inhibitor1 Recommendation i...

Novartis Sacrifices A Flat Base On Lagging Sales Of Its Biggest Moneymaker — Oct 29th, 2024

Novartis stock slumped Tuesday — undercutting the lower boundary of a flat base — after sales of its biggest moneymaker expectations. Continue reading View comments...

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer — Oct 18th, 2024

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer On Friday, Novartis AG (NYSE:NVS) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for ...

Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU — Oct 17th, 2024

Alnylam Pharmaceuticals ALNY announced that it has submitted a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM). Shares of the company gained 4.6% in response to t...

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone — Dec 2nd, 2024

Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged. Continue reading View comments...

Novartis Sacrifices A Flat Base On Lagging Sales Of Its Biggest Moneymaker — Oct 29th, 2024

Novartis stock slumped Tuesday — undercutting the lower boundary of a flat base — after sales of its biggest moneymaker expectations. Continue reading View comments...

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer — Oct 18th, 2024

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment with Kisqali® (ribociclib) in combination with an aromatase inhibitor1 Recommendation i...

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone — Dec 2nd, 2024

Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged. Continue reading View comments...

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer — Oct 18th, 2024

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment with Kisqali® (ribociclib) in combination with an aromatase inhibitor1 Recommendation i...

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer — Oct 18th, 2024

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer On Friday, Novartis AG (NYSE:NVS) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for ...

Novartis Sacrifices A Flat Base On Lagging Sales Of Its Biggest Moneymaker — Oct 29th, 2024

Novartis stock slumped Tuesday — undercutting the lower boundary of a flat base — after sales of its biggest moneymaker expectations. Continue reading View comments...

Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU — Oct 17th, 2024

Alnylam Pharmaceuticals ALNY announced that it has submitted a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM). Shares of the company gained 4.6% in response to t...

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer — Oct 18th, 2024

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment with Kisqali® (ribociclib) in combination with an aromatase inhibitor1 Recommendation i...

Novartis Sacrifices A Flat Base On Lagging Sales Of Its Biggest Moneymaker — Oct 29th, 2024

Novartis stock slumped Tuesday — undercutting the lower boundary of a flat base — after sales of its biggest moneymaker expectations. Continue reading View comments...

Novartis Sacrifices A Flat Base On Lagging Sales Of Its Biggest Moneymaker — Oct 29th, 2024

Novartis stock slumped Tuesday — undercutting the lower boundary of a flat base — after sales of its biggest moneymaker expectations. Continue reading View comments...

Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU — Oct 17th, 2024

Alnylam Pharmaceuticals ALNY announced that it has submitted a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM). Shares of the company gained 4.6% in response to t...

Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU — Oct 17th, 2024

Alnylam Pharmaceuticals ALNY announced that it has submitted a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM). Shares of the company gained 4.6% in response to t...

Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU — Oct 17th, 2024

Alnylam Pharmaceuticals ALNY announced that it has submitted a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM). Shares of the company gained 4.6% in response to t...

Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU — Oct 17th, 2024

Alnylam Pharmaceuticals ALNY announced that it has submitted a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM). Shares of the company gained 4.6% in response to t...

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer — Oct 18th, 2024

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment with Kisqali® (ribociclib) in combination with an aromatase inhibitor1 Recommendation i...

Novartis Sacrifices A Flat Base On Lagging Sales Of Its Biggest Moneymaker — Oct 29th, 2024

Novartis stock slumped Tuesday — undercutting the lower boundary of a flat base — after sales of its biggest moneymaker expectations. Continue reading View comments...

Novartis Sacrifices A Flat Base On Lagging Sales Of Its Biggest Moneymaker — Oct 29th, 2024

Novartis stock slumped Tuesday — undercutting the lower boundary of a flat base — after sales of its biggest moneymaker expectations. Continue reading View comments...

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer — Oct 18th, 2024

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer On Friday, Novartis AG (NYSE:NVS) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for ...

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer — Oct 18th, 2024

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer On Friday, Novartis AG (NYSE:NVS) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for ...

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer — Oct 18th, 2024

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment with Kisqali® (ribociclib) in combination with an aromatase inhibitor1 Recommendation i...

Novartis Sacrifices A Flat Base On Lagging Sales Of Its Biggest Moneymaker — Oct 29th, 2024

Novartis stock slumped Tuesday — undercutting the lower boundary of a flat base — after sales of its biggest moneymaker expectations. Continue reading View comments...

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer — Oct 18th, 2024

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer On Friday, Novartis AG (NYSE:NVS) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for ...

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone — Dec 2nd, 2024

Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged. Continue reading View comments...

Novartis Sacrifices A Flat Base On Lagging Sales Of Its Biggest Moneymaker — Oct 29th, 2024

Novartis stock slumped Tuesday — undercutting the lower boundary of a flat base — after sales of its biggest moneymaker expectations. Continue reading View comments...

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone — Dec 2nd, 2024

Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged. Continue reading View comments...

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer — Oct 18th, 2024

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer On Friday, Novartis AG (NYSE:NVS) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for ...

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone — Dec 2nd, 2024

Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged. Continue reading View comments...

Novartis Sacrifices A Flat Base On Lagging Sales Of Its Biggest Moneymaker — Oct 29th, 2024

Novartis stock slumped Tuesday — undercutting the lower boundary of a flat base — after sales of its biggest moneymaker expectations. Continue reading View comments...

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer — Oct 18th, 2024

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment with Kisqali® (ribociclib) in combination with an aromatase inhibitor1 Recommendation i...

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer — Oct 18th, 2024

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment with Kisqali® (ribociclib) in combination with an aromatase inhibitor1 Recommendation i...

Novartis Sacrifices A Flat Base On Lagging Sales Of Its Biggest Moneymaker — Oct 29th, 2024

Novartis stock slumped Tuesday — undercutting the lower boundary of a flat base — after sales of its biggest moneymaker expectations. Continue reading View comments...

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone — Dec 2nd, 2024

Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged. Continue reading View comments...

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer — Oct 18th, 2024

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment with Kisqali® (ribociclib) in combination with an aromatase inhibitor1 Recommendation i...